131 related articles for article (PubMed ID: 11163031)
1. Determination of xanthine oxidoreductase forms: influence of reaction conditions.
Martí R; Varela E; Pascual C; Segura RM
Clin Chim Acta; 2001 Jan; 303(1-2):117-25. PubMed ID: 11163031
[TBL] [Abstract][Full Text] [Related]
2. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry.
Murase T; Nampei M; Oka M; Ashizawa N; Matsumoto K; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():189-197. PubMed ID: 26673227
[TBL] [Abstract][Full Text] [Related]
3. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
[TBL] [Abstract][Full Text] [Related]
4. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
[TBL] [Abstract][Full Text] [Related]
5. Improved method for measurement of human plasma xanthine oxidoreductase activity.
Liu X; Lin WM; Yan XH; Chen XH; Hoidal JR; Xu P
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 785(1):101-14. PubMed ID: 12535843
[TBL] [Abstract][Full Text] [Related]
6. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
[TBL] [Abstract][Full Text] [Related]
7. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
[TBL] [Abstract][Full Text] [Related]
8. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
[TBL] [Abstract][Full Text] [Related]
9. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography/triple quadrupole mass spectrometry.
Murase T; Oka M; Nampei M; Miyachi A; Nakamura T
J Labelled Comp Radiopharm; 2016 May; 59(5):214-20. PubMed ID: 27006202
[TBL] [Abstract][Full Text] [Related]
10. Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes.
Okuyama T; Shirakawa J; Nakamura T; Murase T; Miyashita D; Inoue R; Kyohara M; Togashi Y; Terauchi Y
Sci Rep; 2021 Feb; 11(1):3768. PubMed ID: 33580173
[TBL] [Abstract][Full Text] [Related]
11. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.
Kawachi Y; Fujishima Y; Nishizawa H; Nagao H; Nakamura T; Akari S; Murase T; Taya N; Omori K; Miyake A; Fukuda S; Takahara M; Kita S; Katakami N; Maeda N; Shimomura I
J Diabetes Investig; 2021 Aug; 12(8):1512-1520. PubMed ID: 33211396
[TBL] [Abstract][Full Text] [Related]
12. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
13. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
[TBL] [Abstract][Full Text] [Related]
14. Increased serum level of xanthine oxidoreductase in liver transplanted patients.
Battelli MG; Ravaioli M; Musiani S; Scicchitano V; Grazi GL; Bolognesi A
J Biol Regul Homeost Agents; 2011; 25(1):77-84. PubMed ID: 21382276
[TBL] [Abstract][Full Text] [Related]
15. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of porcine liver xanthine oxidoreductase mediated N-oxide reduction of cyadox as revealed by docking and mutagenesis studies.
Chen C; Cheng G; Hao H; Dai M; Wang X; Huang L; Liu Z; Yuan Z
PLoS One; 2013; 8(9):e73912. PubMed ID: 24040113
[TBL] [Abstract][Full Text] [Related]
17. Modelling of growth kinetics of isolated Pseudomonas sp. and optimisation of parameters for enhancement of xanthine oxidoreductase production by statistical design of experiments.
Sen S; Sarkar P
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2019; 54(1):65-78. PubMed ID: 30822215
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidoreductase-catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how.
Cantu-Medellin N; Kelley EE
Nitric Oxide; 2013 Nov; 34():19-26. PubMed ID: 23454592
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.
Watanabe K; Shishido T; Otaki Y; Watanabe T; Sugai T; Toshima T; Takahashi T; Yokoyama M; Kinoshita D; Murase T; Nakamura T; Wanezaki M; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Yamauchi S; Yamanaka T; Miyamoto T; Kubota I; Watanabe M
Heart Vessels; 2019 Jan; 34(1):1-8. PubMed ID: 29936631
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes.
Washio K; Kusunoki Y; Tsunoda T; Osugi K; Ohigashi M; Murase T; Nakamura T; Matsuo T; Konishi K; Katsuno T; Namba M; Koyama H
Acta Diabetol; 2020 Jan; 57(1):31-39. PubMed ID: 31093763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
